B-Cell Non-Hodgkin Lymphoma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working
Non-lymphoma Hodgkin's is cancer that starts in the lymphatic system, which is part of the body's immune system. White blood cells called lymphocytes proliferate improperly in non-lymphoma Hodgkin's and can form tumors throughout the body.
Non-lymphoma Hodgkin's is a type of lymphoma that is not Hodgkin's lymphoma. This category encompasses a wide range of subcategories. The most prevalent subtypes are diffuse large B-cell lymphoma and follicular lymphoma. Hodgkin's lymphoma is the other major type of lymphoma.
DelveInsight’s “B-Cell Non-Hodgkin Lymphoma – Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the B-Cell Non-Hodgkin Lymphoma Market Report:
Non-lymphoma Hodgkin's can strike at any age, but it is more common as people get older. It is more common in adults aged 60 and above
In India, B-cell NHL accounts for 80-85% of all NHLs [10, 1314]. The most common subtype of NHL is diffuse large B-cell NHL (60 percent), followed by indolent lymphoma (12-20 percent). T-cell lymphomas make for 10-15% of all cases.
Non-Hodgins' lymphoma (NHL) is the most prevalent hematological disease, accounting for roughly 3% of all cancer diagnoses and deaths worldwide.
NHL accounts for almost 4% of cancer diagnoses in the United States, with a 168 percent rise in incidence since 1975.
To request a sample of the report: https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-marke
B-Cell Non-Hodgkin Lymphoma Symptoms:
Symptoms of the Non-Hodgkin Lymphoma are-
Swollen Lymph nodes can be seen in the Neck, Groin, and armpits area
Pain or Swelling in the Abdominal Area
Body Fatigue
Abrupt Weight loss
Sweating in the night
B-Cell Non-Hodgkin Lymphoma Market
The dynamics of the B-Cell Non-Hodgkin Lymphoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecasted period 2022-2032.
Due to the high prevalence of the Non-Hodgkin Lymphoma, the ongoing market trends are mainly focused on launches of advanced products. Some Key Players in the market are- Genmab
Hoffmann-La Roche, BioInvent International AB, CARsgen Therapeutics Co., Ltd.
Learn more by requesting for sample @ B-Cell Non-Hodgkin Lymphoma Market Landscape
B-Cell Non-Hodgkin Lymphoma Pipeline Therapies:
GEN3009
Epcoritamab
Mosunetuzumab (IV)
Polatuzumab Vedotin
BI1206
Epcoritamab
B-Cell Non-Hodgkin Lymphoma and Key Companies:
Genmab
Hoffmann-La Roche
BioInvent International AB
CARsgen Therapeutics Co., Ltd.
The First Affiliated Hospital of Soochow University
Peking University
Beijing Cancer Hospital
Click here to read more about B-Cell Non-Hodgkin Lymphoma Market Outlook 2032
Related Reports:
B-Cell Non-Hodgkin Lymphoma Pipeline
"B-Cell Non-Hodgkin Lymphoma Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the B-Cell Non-Hodgkin Lymphoma market. A detailed picture of the B-Cell Non-Hodgkin Lymphoma pipeline landscape is provided, which includes the disease overview and B-Cell Non-Hodgkin Lymphoma treatment guidelines.
B-Cell Non-Hodgkin Lymphoma Epidemiology
DelveInsight's 'B-Cell Non-Hodgkin Lymphoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted B-Cell Non-Hodgkin Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Comments
Post a Comment